SPH3127 (Sitokiren), a Novel Renin Inhibitor, Suppresses Colitis Development in Mouse Models of Experimental Colitis
These results demonstrate that SPH3127 is able to effectively block colitis development in mouse experimental colitis models. Its anti-colitogenic activity is achieved at least in part by suppressing mucosal TH1 and TH17 activation while promoting IL-10 production from mucosal CD25+ T cells, thus forming an anti-inflammatory environment in the colonic mucosa.
Authors
- Caleb Muefong (ORCID: https://orcid.org/0000-0001-8817-9188)
- Guangxin Xia (ORCID: https://orcid.org/0000-0002-1570-353X)
- Xuesong Wang (ORCID: https://orcid.org/0000-0003-3259-1880)
- Jing Zhang (ORCID: https://orcid.org/0000-0002-7346-555X)
- Lei Wang (ORCID: https://orcid.org/0000-0002-5071-5800)
- Weicheng Liu (ORCID: https://orcid.org/0000-0001-6360-3544)
- Yan Chun Li (ORCID: https://orcid.org/0000-0001-9937-7630)
- Rajesh Sarkar (ORCID: https://orcid.org/0000-0001-7779-031X)
- Wei Su
- Kenneth W. Locke
- Xin Nakanishi
Institutions
- University of Chicago (US)
- Central Research Institute (IN)
- Shanghai Institute of Pharmaceutical Industry (CN)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1093/ibd/izaf097
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00